Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIAC twice daily versus biphasic insulin aspart 30 twice daily in type 2 diabetes
2008-005768-15Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2009
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing SIAC BID with Biphasic insulin aspart 30 BID (2 arms). Primary endpoints: Change from baseline in HbA1c after 26 weeks of treatment and Non-inferiority of SIAC versus biphasic insulin aspart 30 for HbA1c change at 26 weeks. Started May 2009; status: completed.
02
Drugs
insulin degludec + insulin aspartbiphasic insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-005768-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005768-15.